Stockscreener 앱 받기
4.81
1.26%
0.06
시간 외 거래:
4.80
-0.010
-0.21%
전일 마감가:
$4.75
열려 있는:
$4.67
하루 거래량:
543.75K
Relative Volume:
0.90
시가총액:
$239.99M
수익:
-
순이익/손실:
$-122.31M
주가수익비율:
-1.0653
EPS:
-4.5151
순현금흐름:
$-110.41M
1주 성능:
-6.24%
1개월 성능:
-30.29%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$4.59
$4.83
1주일 범위
$4.52
$5.35
52주 변동 폭
$4.52
$8.5498
Helus Pharma Inc Stock (HELP) Company Profile
Compare HELP vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HELP
Helus Pharma Inc
|
4.81 | 237.00M | 0 | -122.31M | -110.41M | -4.5151 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Helus Pharma Inc Stock (HELP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-02 | 개시 | Jefferies | Buy |
| 2025-03-13 | 개시 | Guggenheim | Buy |
| 2021-11-19 | 다운그레이드 | Maxim Group | Buy → Hold |
Helus Pharma Inc 주식(HELP)의 최신 뉴스
symbol__ Stock Quote Price and Forecast - CNN
Help stock crashes on anxiety trial results, but here’s why Jefferies sees up to 200% upside - MSN
Helus Pharma (CYBN) appoints Jill Conwell as Chief People Officer - Stock Titan
Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer - Bitget
Helus Pharma Adds Chief People Officer as Mental Health Pipeline Advances - TipRanks
CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions - Investing News Network
Neuropsychiatric Innovation Draws Big Pharma Interest and Fresh Investment - Baystreet.ca
HELP Stock Price and Chart — NEO:HELP - TradingView
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
Assessing Cybin (HELP) Valuation After HLP004 Phase 2 Anxiety Data Draws Fresh Attention - simplywall.st
Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results - Yahoo Finance
Cybin (HELP) Is Down 27.3% After Positive HLP004 GAD Phase 2 Data Reported Is The Thesis Intact? - Yahoo Finance
Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder - Sahm
HELP Stock Crashes On Anxiety Trial Results, But Here’s Why Jefferies Sees Up To 200% Upside - Asianet Newsable
Could Helus Pharma’s HLP004 Data Quietly Reframe Cybin’s (HELP) Interventional Psychiatry Investment Story? - simplywall.st
HELP Stock Tanks 22% Despite Strong Phase 2 Results For Anxiety Treatment: Retail Buys The Dip Ignoring Market’s Pessimism - Stocktwits
Helus Pharma’s top-line Phase II data signal detection study for HLP004 - The Pharma Letter
Jefferies reiterates Helus Pharma stock rating on anxiety data By Investing.com - Investing.com Canada
Agencia de ComunicacãoHelus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder - Estadão Blue Studio
Helus Pharma Stock Tumbles As Anxiety Drug Study DisappointsHelus Pharma (NASDAQ:HELP) - Benzinga
Helus Pharma (HELP) Shares Drop Despite Positive Phase 2 Trial R - GuruFocus
Helus Pharma (HELP) Reports Positive Phase 2 Study Results for A - GuruFocus
Cybin’s Helus Pharma Posts Strong Phase 2 Data for HLP004 in Hard-to-Treat Anxiety - TipRanks
Helus stock falls on data for anxiety therapy (HELP:NASDAQ) - Seeking Alpha
Helus Pharma announces topline results in phase 2 signal detection study for Hlp004 in patients with generalized anxiety disorder - marketscreener.com
Helus Pharma Announces Topline Results In Phase 2 Signal Detection Study For Hlp004 In Patients With Generalized Anxiety Disorder - TradingView
Helus Pharma (HELP) Price Target Raised by HC Wainwright & Co. | - GuruFocus
Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments - The AI Journal
Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders - The Malaysian Reserve
From Lab to Clinic: Five CNS Companies Advancing Neuroscience Treatments - Baystreet.ca
Helus Pharma appoints Dr. Freda Lewis-Hall to board of directors - Investing.com India
HELUS Pharma: Transitioning From Psychedelic Research To Late-Stage Clinical Neuroscience - Seeking Alpha
Helus Pharma (Nasdaq: HELP) brings former Pfizer CMO Lewis-Hall onto board - Stock Titan
Helus Pharma appoints Dr. Freda Lewis-Hall to board of directors By Investing.com - Investing.com South Africa
Helus Pharma appoints former Pfizer chief medical officer to board of directors - marketscreener.com
Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee - Toronto Star
Magic Mushrooms, Hard Cash: Compass Pathways' Trial Win, Fast Raise - Finviz
Cybin (Helus Pharma) Names Veteran Pharma Executive Michael Cola as CEO to Drive CNS Growth - The Globe and Mail
Jeffries Highlight Cybin D/B/A Helus Pharma (HELP)'s Science-Driven Psilocybin Therapies as Key Growth Drivers - Finviz
Helus Pharma Inc (HELP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):